SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 1,344 shares, a growth of 78.0% from the September 30th total of 755 shares. Based on an average trading volume of 53,601 shares, the days-to-cover ratio is presently 0.0 days.
SAB Biotherapeutics Price Performance
SABSW stock remained flat at $0.00 during mid-day trading on Monday. SAB Biotherapeutics has a 12 month low of $0.00 and a 12 month high of $0.20. The stock’s fifty day moving average is $0.01 and its two-hundred day moving average is $0.02.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc is a biotechnology company focused on developing antibody-based medicines for infectious diseases, autoimmune conditions and other immune-mediated disorders. The company’s lead programs have included SAB-142, an investigational therapy for immune-mediated disease, and SAB-176, an antibody product candidate designed to address influenza A infections. SAB also developed SAB-185 for the treatment of COVID-19.
The company uses its DiversitAb platform, which involves genetically engineered cattle capable of producing fully human polyclonal antibodies.
Recommended Stories
- Five stocks we like better than SAB Biotherapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
